Abstract
Purpose :
We report the 12-month visual and the anatomical outcomes of naïve macular oedema secondary to retinal vein occlusion (RVO) treated with aflibercept
Methods :
Retrospective analysis of consecutive 34 patients with macular oedema secondary to RVO, 21 branch retinal vein occlusion (BRVO) and 13 central vein occlusion (CRVO), treated with aflibercept during the period from January 2016 to June 2017 with at least 12 months follow up. All patients received loading dose of 3 monthly injections followed by as needed or pro re nata (PRN). Standard assessment included LogMar visual acuity (VA), central retinal thickness (CRT) and slit-lamp biomicroscopy
Results :
8 males and 13 females in BRVO group, mean age was 74±10 years and 8 males and 5 females in CRVO group, mean age 78±10 years. Baseline mean VA was (60±SD14) improved to (65±SD12) letters at 12-months and (45±18SD) improved to (51±20SD) letters at 12 months in the BRVO and CRVO groups respectively. Only one eye with BRVO lost more than 15 letters. At 12-months mean change in the CRT was (-151±SD74) micrometres and (-270±SD183) micrometres in the BRVO and CRVO group respectively. One eye with CRVO received sector panretinal photocoagulation laser and 2 eyes with BRVO received macular laser treatment
Conclusions :
Aflibercept maintained and improved visual (83%) and anatomical (95%) outcomes with no significant adverse events, visual improvement is comparable to real life studies. Our results demonestrate that aflibercept is very good monotherapy in treatment of naïve macular oedema secondary to retinal vein occlusion. Long-term outcomes and comparative studies to switch patients are warranted
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.